Department of Respiratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Academy of Chinese Medical Sciences, The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, China.
Syst Rev. 2024 Aug 5;13(1):210. doi: 10.1186/s13643-024-02621-1.
BACKGROUND: Severe pneumonia has consistently been associated with high mortality. We sought to identify risk factors for the mortality of severe pneumonia to assist in reducing mortality for medical treatment. METHODS: Electronic databases including PubMed, Web of Science, EMBASE, Cochrane Library, and Scopus were systematically searched till June 1, 2023. All human research were incorporated into the analysis, regardless of language, publication date, or geographical location. To pool the estimate, a mixed-effect model was used. The Newcastle-Ottawa Scale (NOS) was employed for assessing the quality of included studies that were included in the analysis. RESULTS: In total, 22 studies with a total of 3655 severe pneumonia patients and 1107 cases (30.29%) of death were included in the current meta-analysis. Significant associations were found between age [5.76 years, 95% confidence interval [CI] (3.43, 8.09), P < 0.00001], male gender [odds ratio (OR) = 1.47, 95% CI (1.07, 2.02), P = 0.02], and risk of death from severe pneumonia. The comorbidity of neoplasm [OR = 3.37, 95% CI (1.07, 10.57), P = 0.04], besides the presence of complications such as diastolic hypotension [OR = 2.60, 95% CI (1.45, 4.67), P = 0.001], ALI/ARDS [OR = 3.63, 95% CI (1.78, 7.39), P = 0.0004], septic shock [OR = 9.43, 95% CI (4.39, 20.28), P < 0.00001], MOF [OR = 4.34, 95% CI (2.36, 7.95), P < 0.00001], acute kidney injury [OR = 2.45, 95% CI (1.14, 5.26), P = 0.02], and metabolic acidosis [OR = 5.88, 95% CI (1.51, 22.88), P = 0.01] were associated with significantly higher risk of death among patients with severe pneumonia. Those who died, compared with those who survived, differed on multiple biomarkers on admission including serum creatinine [Scr: + 67.77 mmol/L, 95% CI (47.21, 88.34), P < 0.00001], blood urea nitrogen [BUN: + 6.26 mmol/L, 95% CI (1.49, 11.03), P = 0.01], C-reactive protein [CRP: + 33.09 mg/L, 95% CI (3.01, 63.18), P = 0.03], leukopenia [OR = 2.63, 95% CI (1.34, 5.18), P = 0.005], sodium < 136 mEq/L [OR = 2.63, 95% CI (1.34, 5.18), P = 0.005], albumin [- 5.17 g/L, 95% CI (- 7.09, - 3.25), P < 0.00001], PaO/FiO [- 55.05 mmHg, 95% CI (- 60.11, - 50.00), P < 0.00001], arterial blood PH [- 0.09, 95% CI (- 0.15, - 0.04), P = 0.0005], gram-negative microorganism [OR = 2.56, 95% CI (1.17, 5.62), P = 0.02], and multilobar or bilateral involvement [OR = 3.65, 95% CI (2.70, 4.93), P < 0.00001]. CONCLUSIONS: Older age and male gender might face a greater risk of death in severe pneumonia individuals. The mortality of severe pneumonia may also be significantly impacted by complications such diastolic hypotension, ALI/ARDS, septic shock, MOF, acute kidney injury, and metabolic acidosis, as well as the comorbidity of neoplasm, and laboratory indicators involving Scr, BUN, CRP, leukopenia, sodium, albumin, PaO/FiO, arterial blood PH, gram-negative microorganism, and multilobar or bilateral involvement. SYSTEMATIC REVIEW REGISTRATION: PROSPERO Protocol Number: CRD 42023430684.
背景:严重肺炎一直与高死亡率相关。我们旨在确定严重肺炎死亡率的相关因素,以帮助降低治疗死亡率。
方法:系统检索了 PubMed、Web of Science、EMBASE、Cochrane Library 和 Scopus 等电子数据库,检索时间截至 2023 年 6 月 1 日。所有人类研究均纳入分析,无论语言、出版日期或地理位置如何。使用混合效应模型进行汇总估计。采用纽卡斯尔-渥太华量表(NOS)评估纳入分析的研究质量。
结果:共纳入 22 项研究,共纳入 3655 例严重肺炎患者和 1107 例死亡病例(30.29%)。研究发现年龄[5.76 岁,95%置信区间(3.43,8.09),P<0.00001]、男性性别[比值比(OR)=1.47,95%置信区间(1.07,2.02),P=0.02]与严重肺炎死亡风险显著相关。合并肿瘤[OR=3.37,95%置信区间(1.07,10.57),P=0.04]以及并发症如舒张压低[OR=2.60,95%置信区间(1.45,4.67),P=0.001]、ALI/ARDS[OR=3.63,95%置信区间(1.78,7.39),P=0.0004]、感染性休克[OR=9.43,95%置信区间(4.39,20.28),P<0.00001]、多器官功能衰竭[OR=4.34,95%置信区间(2.36,7.95),P<0.00001]、急性肾损伤[OR=2.45,95%置信区间(1.14,5.26),P=0.02]和代谢性酸中毒[OR=5.88,95%置信区间(1.51,22.88),P=0.01]与严重肺炎患者死亡风险显著相关。与存活者相比,死亡者入院时的多项生物标志物存在差异,包括血清肌酐[Scr:增加 67.77 mmol/L,95%置信区间(47.21,88.34),P<0.00001]、血尿素氮[BUN:增加 6.26 mmol/L,95%置信区间(1.49,11.03),P=0.01]、C 反应蛋白[CRP:增加 33.09 mg/L,95%置信区间(3.01,63.18),P=0.03]、白细胞减少症[OR=2.63,95%置信区间(1.34,5.18),P=0.005]、血清钠<136 mEq/L[OR=2.63,95%置信区间(1.34,5.18),P=0.005]、白蛋白[-5.17 g/L,95%置信区间(-7.09,-5.25),P<0.00001]、动脉血氧分压/吸入氧浓度[PaO/FiO:减少 55.05 mmHg,95%置信区间(-60.11,-50.00),P<0.00001]、动脉血 pH 值[-0.09,95%置信区间(-0.15,-0.04),P=0.0005]、革兰氏阴性菌[OR=2.56,95%置信区间(1.17,5.62),P=0.02]和多肺叶或双侧受累[OR=3.65,95%置信区间(2.70,4.93),P<0.00001]。
结论:年龄较大和男性性别可能使严重肺炎患者面临更大的死亡风险。舒张压低、ALI/ARDS、感染性休克、多器官功能衰竭、急性肾损伤和代谢性酸中毒等并发症以及肿瘤合并症、涉及 Scr、BUN、CRP、白细胞减少症、血清钠、白蛋白、PaO/FiO、动脉血 pH 值、革兰氏阴性菌和多肺叶或双侧受累的实验室指标也可能显著影响严重肺炎的死亡率。
系统评价注册:PROSPERO 注册号:CRD 42023430684。
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2005-7-20
Cochrane Database Syst Rev. 2022-2-24
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2012-5-16
Cochrane Database Syst Rev. 2023-9-13
Front Med (Lausanne). 2025-7-23
Front Med (Lausanne). 2025-7-3
Front Med (Lausanne). 2025-3-19
J Cardiothorac Surg. 2025-1-23
Clin J Am Soc Nephrol. 2023-1-1
Intern Emerg Med. 2022-9
Curr Opin Infect Dis. 2022-4-1
Front Public Health. 2021
Immunity. 2021-5-11
Adv Exp Med Biol. 2021